OptimizeRx Corp (NASDAQ: OPRX)’s stock price has gone rise by 14.43 in comparison to its previous close of 8.80, however, the company has experienced a 8.05% increase in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-26 that 1Q24 revenue expected to grow over 40% year-over-year and come in between $18.5 – $19.2 million First quarter revenue and adjusted EBITDA to come in ahead of consensus DAAP adoption and cross selling activities are tracking ahead of internal expectations WALTHAM, Mass., April 26, 2024 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, is providing a business update for 2024 and is preannouncing preliminary, unaudited results for select financials for the first quarter of 2024.
Is It Worth Investing in OptimizeRx Corp (NASDAQ: OPRX) Right Now?
The stock has a 36-month beta value of 1.08. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for OPRX is 15.97M, and at present, short sellers hold a 3.92% of that float. On April 26, 2024, the average trading volume of OPRX was 122.81K shares.
OPRX’s Market Performance
OPRX’s stock has seen a 8.05% increase for the week, with a -17.12% drop in the past month and a -30.07% fall in the past quarter. The volatility ratio for the week is 5.95%, and the volatility levels for the past 30 days are at 5.45% for OptimizeRx Corp The simple moving average for the past 20 days is -3.28% for OPRX’s stock, with a -11.89% simple moving average for the past 200 days.
Analysts’ Opinion of OPRX
Many brokerage firms have already submitted their reports for OPRX stocks, with JMP Securities repeating the rating for OPRX by listing it as a “Mkt Outperform.” The predicted price for OPRX in the upcoming period, according to JMP Securities is $15 based on the research report published on April 04, 2024 of the current year 2024.
Barclays, on the other hand, stated in their research note that they expect to see OPRX reach a price target of $15. The rating they have provided for OPRX stocks is “Equal Weight” according to the report published on January 03rd, 2024.
B. Riley Securities gave a rating of “Buy” to OPRX, setting the target price at $30 in the report published on February 02nd of the previous year.
OPRX Trading at -21.30% from the 50-Day Moving Average
After a stumble in the market that brought OPRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.50% of loss for the given period.
Volatility was left at 5.45%, however, over the last 30 days, the volatility rate increased by 5.95%, as shares sank -17.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.24% lower at present.
During the last 5 trading sessions, OPRX rose by +7.83%, which changed the moving average for the period of 200-days by -32.45% in comparison to the 20-day moving average, which settled at $10.31. In addition, OptimizeRx Corp saw -29.63% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OPRX starting from Odence-Ford Marion, who sale 4,000 shares at the price of $15.19 back on Jan 09 ’24. After this action, Odence-Ford Marion now owns 11,114 shares of OptimizeRx Corp, valued at $60,751 using the latest closing price.
Stock Fundamentals for OPRX
Current profitability levels for the company are sitting at:
- -0.18 for the present operating margin
- 0.59 for the gross margin
The net margin for OptimizeRx Corp stands at 9.06. The total capital return value is set at -0.08. Equity return is now at value -13.90, with -11.05 for asset returns.
Based on OptimizeRx Corp (OPRX), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -0.2. The debt to equity ratio resting at 0.29. The interest coverage ratio of the stock is 0.02.
Currently, EBITDA for the company is -10.82 million with net debt to EBITDA at -2.12. When we switch over and look at the enterprise to sales, we see a ratio of 2.87. The receivables turnover for the company is 1.92for trailing twelve months and the total asset turnover is 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.04.
Conclusion
To sum up, OptimizeRx Corp (OPRX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
